Relative Bioavailability Study of CC-292

NCT02433457 | Completed Phase 1

• 1 other identifier: CC-292-CP-002
• Study Type: interventional
• Target: 24
• Locations: 1 country
• Sites: 1

Brief Summary

To evaluate the PK profile of the newly developed CC-292 SDD formulation compared to CC-292 P22 tablet.

Conditions

Healthy Volunteers

Keywords

Healthy Volunteers; CC-292; Open-Label; Bioavailability Pharmacokinetics; Phase I

Outcome Measures

Primary Outcomes (11)

• Pharmacokinetics - Cmax

  Maximum observed concentration in plasma

  48 hours

• Pharmacokinetics - AUC 0-t

  Area under the plasma concentration-time curve from time zero to the last measured time point

  48 hours

• Pharmacokinetics - AUC 0-24

  Area under the plasma concentration-time curve to 24 hours post dose

  48 hours

• Pharmacokinetics - AUC 0-∞

  Area under the plasma concentration-time curve from time zero extrapolated to infinity

  48 hours

• Pharmacokinetics - %AUCextrap

  Percent Area under the plasma concentration-time curve extrapolated

  48 hours

• Pharmacokinetics - Frel

  Relative bioavailability of the CC-292 SDD formulation compared to the reference P22 formulation

  48 hours

• Pharmacokinetics - Tmax

  Time to Cmax

  48 hours

• Pharmacokinetics - λz

  Terminal disposition rate constant

  48 hours

• Pharmacokinetics - t1/2

  Terminal half-life

  48 hours

• Pharmacokinetics - CL/F

  Apparent clearance

  48 hours

• Pharmacokinetics - Vz/F

  Apparent volume of distribution

  48 hours

Secondary Outcomes (1)

• Adverse Events (AEs)

  Approximatly 52 days

Study Arms (7)

CC-292 SDD (Spray Dried Dispersion)300mg - Fasted Condition

EXPERIMENTAL

Single oral dose of 300 mg CC-292 SDD under fasted conditions (100 mg SDD x 3 tablets)

Drug: CC-292

CC-292 SDD 300mg - Fed Condition

EXPERIMENTAL

Single oral dose of 300 mg CC-292 SDD under fed conditions (100 mg SDD x 3 tablets)

Drug: CC-292

375mg P22 - Fasted condition

EXPERIMENTAL

Single oral dose of 375 mg P22 under fasted conditions (125 mg P22 x 3)

Drug: CC-292

375mg P22 Fed Condition

EXPERIMENTAL

Single oral dose of 375 mg P22 under fed conditions (125 mg P22 x 3)

Drug: CC-292

CC-292 SDD 100 mg Fasted Condition

EXPERIMENTAL

Single oral dose of 100 mg CC-292 SDD under fasted conditions

Drug: CC-292

SDD plus OMP (Oral Omeprazole)

EXPERIMENTAL

Single oral dose of 300 mg CC-292 SDD under fasted conditions (100 mg SDD x 3 tablets) in the presence of 40 mg

Drug: CC-292; Drug: Oral Omeprazole (OMP)

P22 plus OMP

EXPERIMENTAL

Single oral dose of 375 mg P22 under fasted conditions (125 mg P22 x 3) in the presence of 40 mg oral OMP

Drug: CC-292; Drug: Oral Omeprazole (OMP)

Interventions

CC-292 DRUG

375mg P22 - Fasted condition; 375mg P22 Fed Condition; CC-292 SDD (Spray Dried Dispersion)300mg - Fasted Condition; CC-292 SDD 100 mg Fasted Condition; CC-292 SDD 300mg - Fed Condition; P22 plus OMP; SDD plus OMP (Oral Omeprazole)

Oral Omeprazole (OMP) DRUG

P22 plus OMP; SDD plus OMP (Oral Omeprazole)

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Must understand and voluntarily sign a written Informed Consent Form (ICF) prior to any study-related assessments/procedures being conducted.
• Must be able to communicate with the Investigator, understand, and comply with the requirements of the study, and agree to adhere to restrictions and examination schedules.
• Must be a male or female subject from any race between 18 to 65 years of age (inclusive) at the time of signing the ICF, and in good health as determined by Physical Examinations (PE).
• Must comply with the following acceptable forms of contraception:
• Male subjects (including those who have had a vasectomy) who engage in activity in which conception is possible must use barrier contraception with male condoms NOT made out of natural animal membrane (e.g., latex or polyurethane condoms are acceptable) while on study drug, and for at least 90 days after the last dose of study drug.
• Females of childbearing potential (FCBP) 1 must have a negative pregnancy test at Screening and at Baseline (i.e., on Day -1). FCBP who engage in activity in which conception is possible must agree to use one of the following forms of contraception during their entire participation in the study and for at least 30 days after administration of the last dose of study drug:
• Option 1: Any one of the following: non-oral hormonal contraception (e.g., injection, implant, transdermal patch, vaginal ring); intrauterine device; tubal ligation; or a partner with a vasectomy; OR
• Option 2: Oral contraceptive pills PLUS one additional barrier method of the following: (a) male or female condom NOT made out of natural animal membrane (e.g., latex or polyurethane is acceptable); (b) diaphragm with spermicide; (c) cervical cap with spermicide; or (d) contraceptive sponge with spermicide; OR
• Option 3: TWO of the following barrier methods: (a) male or female condom NOT made out of natural animal membrane (e.g., latex or polyurethane is acceptable); (b) diaphragm with spermicide; (c) cervical cap with spermicide; or (d) a contraceptive sponge with spermicide.
• Note: All other females must have been surgically sterilized for at least 6 months before Screening (proper documentation required), or be postmenopausal (defined as 24 months without menses before Screening, and an estradiol level of \< 30 pg/mL and a plasma Follicle Stimulating Hormone (FSH) level \> 40 IU/L at Screening).
• Must have a Body Mass Index (BMI) between 18 and 33 kg/m2 (inclusive).
• No clinically significant laboratory test results, as determined by the Investigator.
• Must be afebrile, with supine systolic BP of 90 to 140 mmHg, a supine diastolic Blood Pressure (BP) of 60 to 90 mmHg, and pulse rate of 40 to 110 bpm.
• Must have a normal or clinically acceptable 12-lead Electrocardiogram (ECG) at Screening. Male subjects must have a QTcF value ≤ 430 msec. Female subjects must have a QTcF value ≤ 450 msec.

You may not qualify if:

• Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study.
• Any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study, or confounds the ability to interpret data from the study.
• Use of any prescribed systemic or topical medication (including but not limited to antibiotics, analgesics, anesthetics, etc.) prior to 30 days of the first dose administration, unless Sponsor agreement is obtained.
• Use of any non-prescribed systemic or topical medication (including vitamin/mineral supplements, and herbal medicines) within 7 days of the first dose administration, unless Sponsor agreement is obtained.
• Any surgical or medical condition possibly affecting drug absorption, distribution, metabolism and excretion (e.g., bariatric procedure), or plans to have elective or medical procedures during the conduct of the trial. Subjects post cholecystectomy and post appendectomy may be included.
• Exposure to an investigational drug within 30 days prior to the first dose administration or 5 half-lives of that investigational drug, if known (whichever is longer).
• Donated blood or plasma prior to 4 weeks before the first dose administration to a blood bank or blood donation center.
• History of multiple drug allergies (i.e., two or more);
• History of drug abuse (as defined by the current version of the Diagnostic and Statistical Manual \[DSM\]) prior to 2 years before first dose administration, or a positive drug screen reflecting consumption of illicit drugs.
• History of alcohol abuse (as defined by the current version of the DSM) prior to 2 years before dosing, or a positive alcohol screen.
• Known to have hepatitis, or known to be a carrier of the Hepatitis B Surface Antigen (HBsAg), or Hepatitis C Virus Antibody (HCVAb), or have a positive result to the test for HBsAg, HCVAb, or Human Immunodeficiency Virus (HIV) antibodies at Screening.
• History of smoking or the use of nicotine containing products prior to 3 months of Screening by self reporting.
• Female subjects lactating or breastfeeding a child.

Sponsors & Collaborators

• Celgene: lead

Study Sites (1)

Covance Clinical Research unit

Evansville, Indiana, 47710, United States

Location

Related Publications (1)

• Cheng Y, Liu L, Xue Y, Zhou S, Li Y. An Open Label, Phase 1, Randomized, Seven-treatment, Seven-period, Crossover Study to Assess the Relative Bioavailability, pH Effect, Food Effect, and Dose Proportionality of CC-292, a Potent and Orally Available Bruton's Tyrosine Kinase Inhibitor. Eur J Drug Metab Pharmacokinet. 2022 Jul;47(4):579-592. doi: 10.1007/s13318-022-00776-7. Epub 2022 Jun 3.

  PMID: 35657581 DERIVED

MeSH Terms

Interventions

spebrutinib; Omeprazole

Intervention Hierarchy (Ancestors)

2-Pyridinylmethylsulfinylbenzimidazoles; Sulfoxides; Sulfur Compounds; Organic Chemicals; Pyridines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Benzimidazoles; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring

Study Officials

• Daniel Weiss, MD

  Celgene Corporation

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 26, 2015
• First Posted: May 5, 2015
• Study Start: May 26, 2014
• Primary Completion: September 26, 2014
• Study Completion: September 26, 2014
• Last Updated: August 13, 2020

Record last verified: 2020-08

Locations

US (1)